Relationship between Preoperative Serum CA15-3 and CEA Levels and Clinicopathological Parameters in Breast Cancer

Abstract

Background: CEA and CA 15.3 serum tumor markers are currently used in clinical practice for monitoring therapy. The aim of this study was to evaluate serum level of these markers among healthy females and invasive breast carcinoma (IBC) patients and to determine any relationships with clinicopathological factors. Materials and Methods: 60 Iranian females were enrolled in this study, 30 healthy and 30 diagnosed with breast cancer who had not received any preoperative chemotherapy or hormone therapy. Enzyme linked immunosorbent assays were used for the quantitative determination of the cancer associated antigens, CEA and MUC1 (CA15-3). Results: The serological levels of CEA and CA15-3 (5.0033±0.49 µg/L and 178.1667±15.11 U/ml) in the breast cancer patients were significantly higher (p=0.00) than the serum levels of normal controls (1.1237±0.11 µg/L and 21.13±3.058 U/ml). Regarding the CEA marker, a significant correlation with grade of tumor was shown. Furthermore, there was a low correlation between CA15-3 and CEA marker with correlation coefficient r=0.08. Conclusions: Collectively, markedly high levels of CEA and CA15-3 were found in our patients, pointing to their use as additional tools after clinical diagnosis.

Comparison of breast cancer risk factors among molecular subtypes: A case‐only study

“…Similar to our results, Moazzey et al. reported that CA153 and CEA were not significantly different among different subgroups . We found that hormones such as PRL and testosterone were significantly different in different subtypes of breast cancer.…”

Significant Correlation between Salivary and Serum Ca 15-3 in Healthy Women and Breast Cancer Patients

“…This is the case of CA 15-3, it is considered the most reliable marker in breast cancer. The expression of CA15-3 increases significantly in most breast carcinomas (Frenette et al, 1994;Toth et al, 2008;Moazzezy et al, 2014). It was also shown that the rate of CA15-3 is correlated with tumor size, which reflects the stage of the disease (Clinton et al, 2003;Nicolini et al, 2008;Atoum et al, 2012;Zhang et al, 2013).…”

A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years

“…3,18 Previous research studies have shown that breast tumors are associated with systemic changes in both serum protein biomarkers (SPBs) and tumor-associated autoantibodies (TAAbs). [19][20][21][22][23][24][25][26][27] A very limited number of protein biomarkers, such as the estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, cancer-associated antigens (CA27.29 and CA15-3), and carcinoembryonic antigen are currently used for prognosis and treatment monitoring, but their utility in detecting early BC has not been confirmed. 28,29 In Figure 1 Provista-001 and Provista-002 Cohort One (Clinicaltrials.gov Identifiers NCT01839045 and NCT02078570) Clinical Breast Cancer November 2017 -517…”